Alzheimer's blood marker may help estimate cognitive impairment risk up to 10 years ahead
Researchers say p-tau217 blood levels can translate into personalized five- and 10-year dementia risk estimates, but the test is not yet recommended for routine screening.
- Researchers published a study in JAMA detailing a new blood test for advanced Alzheimer disease, developed with Alamar Biosciences to track the extent of tau tangle accumulation in the brain.
- Existing blood tests identify early Alzheimer disease changes but lack information on advanced tangle buildup, which is more closely associated with cognitive impairment and disease severity.
- Investigators analyzed blood samples from 521 brain donors and 207 imaging participants, finding biomarker concentrations 25.2 to 50.5 times higher in advanced pathology; the test requires just 35 µL of plasma.
- The assay accurately distinguished participants with tau pathology, achieving performance comparable to mass spectrometry, said Nicholas Ashton, PhD, senior director of Banner Sun Health Research Institute's Fluid Biomarker Program.
- Although not yet available for clinical use, the test offers a scalable way to stage Alzheimer disease and select patients for Clinical Trials, helping doctors make better treatment decisions.
14 Articles
14 Articles
A Mayo Clinic model uses p-tau217 blood levels, age, sex and genetics to estimate future cognitive impairment risk—but it is not a diagnosis or recommended for routine screening.
A Mayo Clinic study found that p-tau217 blood levels combined with age, sex and genetic risk can estimate five- and 10-year cognitive impairment risk, though the model is not diagnostic.
Researchers create new blood test to better measure advanced Alzheimer's disease
Washington: Researchers at Banner Health, Lund University in Sweden and other renowned international collaborators have demonstrated the first scalable blood test that measures a protein fragment called eMTBR-tau that tracks the buildup of tau tangles - a key sign of Alzheimer's disease.In a study published in Journal of the American Medical Association (JAMA), the newly developed blood test accurately detected advanced tau pathology and showed …
Alzheimer's blood marker may help estimate cognitive impairment risk up to 10 years ahead
A blood biomarker for Alzheimer's disease may help estimate a cognitively healthy person's risk of developing mild cognitive impairment or dementia over the next five or 10 years, according to a new Mayo Clinic study in JAMA Neurology.
Coverage Details
Bias Distribution
- 82% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium













